Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

41.12 USD -0.11 (-0.25%)
Streaming Delayed Price Updated: 9:55 AM EST, Nov 24, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for... 
From Business Wire News Releases
OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites
Collaboration Will Advance Comprehensive Genomic Profiling, Clinical Trials and Real-World Data Studies for Cancer Patients 
From PR Newswire
Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)
Consortium aims to make comprehensive genomic profiling accessible to advanced cancer patients in the U.S. to inform medical management and improve patient outcomes. 
From PR Newswire
Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer
From GlobeNewswire News Releases
Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual Meeting
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American... 
From Business Wire News Releases
Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer
- Lung cancer causes more than 1.7 million deaths worldwide each year, with NSCLC accounting for about 85 percent of all cases[1] 
From PR Newswire
Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19
Roche Obtains Exclusive Right to Develop and Distribute AT-527 Outside the United States 
From GlobeNewswire News Releases
Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination... 
From Business Wire News Releases
Dyno Therapeutics Enters Collaboration and License Agreement With Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies
Dyno Tx Enters Collaboration and License Agreement with Roche to Develop Next-Gen AAV Gene Therapy Vectors for CNS Diseases, Liver-Directed Therapies 
From Business Wire News Releases
NetworkNewsAudio – 180 Life Sciences Corp. Dedicated to Developing Groundbreaking Anti-Inflammatory Drugs
From InvestorBrandNetwork
Judge Rules Tamiflu-Maker Hoffman-La Roche Must Answer Whistleblower Fraud Claims
Lawsuit seeks more than $4B taxpayer recovery for Tamiflu false claims 
From PR Newswire
Solving One of the Largest Drivers of Disease: Inflammation
From InvestorBrandNetwork
Solving One of the Largest Drivers of Disease: Inflammation
NetworkNewsWire Editorial Coverage 
From PR Newswire
Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi™ (risdiplam) in infants aged 2-7 months with... 
From Business Wire News Releases
Inflazome Announces Acquisition by Roche
Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are... 
From Business Wire News Releases
Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical... 
From Business Wire News Releases
Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia... 
From Business Wire News Releases
New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data that show Ocrevus® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting... 
From Business Wire News Releases
New Data Show Genentech’s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new Enspryng™ (satralizumab-mwge) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum... 
From Business Wire News Releases
Genentech Expands Its Multiple Sclerosis Portfolio With Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus (ocrelizumab)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the initiation of an innovative Phase III clinical trial program for its investigational medicine fenebrutinib in... 
From Business Wire News Releases
Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adults... 
From Business Wire News Releases
Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) data will be presented at... 
From Business Wire News Releases
Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that Genentech and Roche are joining forces with Regeneron in the fight against COVID-19 to develop, manufacture and... 
From Business Wire News Releases
ADDING MULTIMEDIA FDA Approves Genentech’s Enspryng for Neuromyelitis Optica Spectrum Disorder
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng™ (satralizumab-mwge) as the first and only... 
From Business Wire News Releases
FDA Accepts Application for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All Indications
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental Biologics License Application... 
From Business Wire News Releases
Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, M.D., Ph.D., as Chief Medical Officer
From GlobeNewswire News Releases
Genentech Provides Update on Phase III Studies of Etrolizumab in People With Moderately to Severely Active Ulcerative Colitis
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced topline results from its Phase III study program evaluating the investigational medicine etrolizumab in people with... 
From Business Wire News Releases
ADDING MULTIMEDIA FDA Approves Genentech’s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam) for treatment of spinal muscular... 
From Business Wire News Releases
Genentech Provides Update on Phase III Study of Tecentriq in Combination With Paclitaxel for People With Metastatic Triple-Negative Breast Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel... 
From Business Wire News Releases
Spark Therapeutics Recognized for Fourth-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.